Structure of LXE408

kinetoplastid-selective proteasome inhibitor

oral antileishmanial in Ph. I in HV

From 3M cmpd antiprolif. screen + opt.

J. Med. Chem., Jul. 29, 2020

Novartis (GNF), San Diego, CA

LXE408 is an oral antileishmanarial compound that selectively targets the kinetoplastid proteosome vs. the mammalian proteosome. The prior candidate, GNF6702, had solubility-limited oral absorption, which could have been addressed with…

 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.